Singer, CF; Tan, YY; Fitzal, F; Steger, GG; Egle, D; Reiner, A; Rudas, M; Gruber, C; Bartsch, R; Fridrik, M; Seifert, M; Exner, R; Balic, M; Bago-Horvath, Z; Filipits, M; Gnant, M.
Pathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancer
CANCER RES. 2017; 77: -San Antonio Breast Cancer Symposium; DEC 06-10, 2016; San Antonio, TX.
Doi: 10.1158/1538-7445.SABCS16-P1-09-10
[Poster]
Web of Science
FullText
FullText_MUG